Medifast (NYSE: MED) released its third-quarter financial guidance on Monday, outlining a wide variance in expected performance compared to analyst consensus. The New York-listed health and wellness company projects GAAP earnings per share (EPS) between $(0.65) and $(0.15), while sales are forecasted to range from $60.000 million to $80.000 million. This guidance introduces significant uncertainty for investors, as the lower end of the sales estimate falls below the $67.700 million consensus, while the upper end suggests potential upside if market conditions improve.

The filing highlights a divergence in expectations for profitability versus top-line growth. Analysts had estimated GAAP EPS at $(0.62), placing the midpoint of Medifast’s guidance range near consensus but allowing for a wider spread of outcomes. The broad sales band of $20.000 million indicates volatility in revenue drivers, potentially reflecting fluctuations in consumer demand or supply chain dynamics that management has not yet fully resolved.

Key Financial Metrics

What the Numbers Show

The most notable aspect of this guidance is the asymmetry in the sales projection. While the EPS guidance center aligns closely with the $(0.62) estimate, the sales range spans from $17.700 million below to $12.300 million above the $67.700 million consensus. This suggests that while cost structures may be relatively fixed, revenue generation remains highly variable. Investors should monitor subsequent disclosures for clarity on whether the lower bound represents a stress scenario or a baseline expectation, as the current data does not specify probability weights for either outcome.

Medifast, the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, will announce financial results for the quarter ended June 30, 2026, on Monday, August 3, 2026, after market close. The announcement will provide insights into the company's performance for the second quarter of FY26. A conference call is scheduled to discuss the results, with additional comments and details from leadership.

Conference Call Details

The conference call will begin at 4:30 p.m. ET on August 3, 2026. Company participants will include Nick Johnson, Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The call will be broadcast live over the Internet and hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com . Alternatively, listeners can access the webcast directly at https://viavid.webcasts.com/starthere.jsp?ei=1768081&tp_key=644d7ae69f .

To join via telephone, listeners may dial (201) 389-0879. The webcast will be archived online and available through November 3, 2026. A telephonic playback will be available from 8:30 p.m. ET on August 3, 2026, through August 10, 2026. Participants can dial (412) 317-6671 and enter access code 13761321 to hear the playback.

About Medifast

Medifast (NYSE: MED) is a metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy. The company's holistic approach integrates science-backed plans and products, personal 1:1 coaching, a supportive community, and behavioral science support to develop healthy habits. Medifast has introduced Metabolic Synchronization®, a breakthrough science targeting metabolic dysfunction through a comprehensive system focused on fat loss, lean mass preservation, and long-term health. Backed by more than 45 years of clinical heritage, Medifast continues to advance its mission of lifelong transformation through metabolic science and human connection.